MOREPENLAB — Morepen Laboratories Share Price
Last trade - 00:00- IN₹67.69bn
- IN₹69.24bn
- IN₹18.06bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.43 | ||
| Price to Tang. Book | 6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.47 | ||
| EV to EBITDA | 33 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.04% | ||
| Return on Equity | 11.7% | ||
| Operating Margin | 8.92% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 15,468.27 | 14,175.3 | 16,904.33 | 18,115.76 | 18,056.92 | n/a | n/a | 8.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -9.12 | -60.63 | +144.27 | +17.21 | -38.52 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Directors
- Sushil Suri CHM (50)
- Vipul Srivatava CCO (33)
- Ajay Sharma CCO
- Arun Sinha EDR (68)
- Anju Suri DRC (51)
- Savita .. NID
- Manoj Joshi NID (57)
- Sukhcharan Singh NID (71)
- Bhupender Wadhwa NID (49)
- Last Annual
- March 31st, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- December 1st, 1984
- Public Since
- November 16th, 1992
- No. of Shareholders
- 447,286
- No. of Employees
- 1,919
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 547,953,699
- Address
- Village Malkumajra, Nalagarh Road,Baddi, GURGAON, 122016
- Web
- https://www.morepen.com/
- Phone
- +91 1244892000
- Auditors
- S.P Babuta & Associates
Latest News for MOREPENLAB
Upcoming Events for MOREPENLAB
Q2 2027 Morepen Laboratories Ltd Earnings Release
Q3 2027 Morepen Laboratories Ltd Earnings Release
Similar to MOREPENLAB
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 04:11 UTC, shares in Morepen Laboratories are trading at IN₹123.54. This share price information is delayed by 15 minutes.
Shares in Morepen Laboratories last closed at IN₹123.54 and the price had moved by +151.92% over the past 365 days. In terms of relative price strength the Morepen Laboratories share price has outperformed the S&P BSE 100 Index by +183.82% over the past year.
The overall consensus recommendation for Morepen Laboratories is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Morepen Laboratories dividend yield is 0.16% based on the trailing twelve month period.
Last year, Morepen Laboratories paid a total dividend of IN₹0.20, and it currently has a trailing dividend yield of 0.16%.Looking ahead, the next dividend pay date is 2026-10-26.
We do not have data on when Morepen Laboratories is to next pay dividends. The historic dividend yield on Morepen Laboratories shares is currently 0.16%.
To buy shares in Morepen Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹123.54, shares in Morepen Laboratories had a market capitalisation of IN₹67.69bn.
Here are the trading details for Morepen Laboratories:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: MOREPENLAB
Based on an overall assessment of its quality, value and momentum Morepen Laboratories is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Morepen Laboratories. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +214.64%.
As of the last closing price of IN₹123.54, shares in Morepen Laboratories were trading +96.82% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Morepen Laboratories PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹123.54.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Morepen Laboratories' management team is headed by:
- Sushil Suri - CHM
- Vipul Srivatava - CCO
- Ajay Sharma - CCO
- Arun Sinha - EDR
- Anju Suri - DRC
- Savita .. - NID
- Manoj Joshi - NID
- Sukhcharan Singh - NID
- Bhupender Wadhwa - NID